Immune checkpoint inhibitor products come under biologic therapeutic products. Biologic manufacturers require similar kind of approvals such as drugs from the U.S. Food & Drug Administration prior to bringing the product into market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Initiatives undertaken by the governments include funding is expected to drive growth of the immune checkpoint inhibitors market. For instance, in 2017, National Institutes of Health partnered with 11 leading biopharmaceutical companies such as AbbVie and Amgen, Inc. to accelerate development of new immunotherapies.

Market Dynamics

Global Immune checkpoint inhibitors market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline of immune checkpoint inhibitor combination therapies. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immune checkpoint inhibitors combination therapies in the pipeline. Immune checkpoint inhibitors has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost global immune checkpoint inhibitors market growth over the forecast period.

Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune checkpoint inhibitors market

Immune checkpoint inhibitor is gaining significant traction as an efficient therapy for cancer treatment worldwide owing to less side effects, and targeted therapeutic effect. Therefore, various pharmaceuticals, biotech companies, universities, and cancer centers are focusing on investing in this segment. According to the Tufts Center for the Study of Drug Development (CSDD) report, 2016, currently, over 130 biotech and 20 pharma companies are developing immuno-oncology therapies, thereby fueling immune checkpoint inhibitors market growth in the forecast period. Also, according to the New York-based, Cancer Research Institute (CRI), 2017, currently 2,004 immuno-oncology agents including 940 in clinical stage and 1,064 in preclinical stage are under development. Leading players are actively investing in research and development in oncology treatment through various collaborations and individual research studies, owing to benefits associated with immune-oncology therapies. Advent of innovative immune-oncology therapies such as immune checkpoint inhibitors, have supported growth of the market. For instance, in 2016, AbbVie and the University of Texas MD Anderson Cancer Center entered into a three-year agreement for focusing on immune system’s complete potential to fight against cancer.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2560

Some of the major players operating in the immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.

Detailed Segmentation:

Global Immune Checkpoint Inhibitors Market, By Drug Class:
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
Global Immune Checkpoint Inhibitors Market, By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Immune Checkpoint Inhibitors Market, By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]